Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5052W HIGH $16.33
Volume
1.75 M
Value Traded
119.13 M
Short % Float
25.68%
-0.23%Week
-9.76%1 Month
+18.65%3 Month
+173.95%6 Month
-86.5%5 Year
-67.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.22 B
EPS (TTM)
-3.15
P/E Ratio
-
Ent. Value
1.11 B
Total Shares
93.80 M
Float Shares
88.61 M
Insiders
5.95%
Institutions
103.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
REPL Catalyst Timeline
Dated clinical, regulatory and corporate events for Replimune Group, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Replimune Group, Inc.
330Total events
12Upcoming
82Tier-1 (high impact)
2018 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchTUDRIQEVApprovedPost-Market
TUDRIQEV now commercially available in the U.S.
unresectable advanced cutaneous melanomasource ↗
●Enrollment UpdateRP1FiledTrial
IGNYTE-3 confirmatory trial actively enrolling
advanced melanomasource ↗
▲FDA ApprovalTUDRIQEVApprovedFDA Decision
FDA granted accelerated approval to TUDRIQEV in combination with nivolumab
unresectable advanced cutaneous melanomasource ↗
▲Full ResultsTUDRIQEVApprovedClinical Data
IGNYTE study data published in Journal of Clinical Oncology
advanced melanomasource ↗
▲Product LaunchTUDRIQEVApprovedPost-Market
Replimune focused on delivering TUDRIQEV to patients
advanced melanomasource ↗
●PDUFA DateRP1FiledRegulatory Filing
FDA target action date for BLA resubmission
advanced melanomasource ↗
▲Accelerated ApprovalTUDRIQEVApprovedFDA Decision
TUDRIQEV receives FDA accelerated approval for advanced melanoma
unresectable advanced cutaneous melanomasource ↗
▲AdCom OutcomeRP1FiledAdvisory Committee
FDA CTGTAC voted 10-3 that IGNYTE efficacy results are evaluable and clinically meaningful
advanced melanomasource ↗
◆AdCom ScheduledRP1FiledAdvisory Committee
Advisory committee meeting expected in late July 2026 for RP1
advanced melanomasource ↗
▲FDA Filing AcceptedRP1FiledRegulatory Filing
FDA accepted for review the resubmission of BLA for RP1 in combination with nivolumab for advanced melanoma
advanced melanomasource ↗
▲FDA Filing AcceptedRP1FiledRegulatory Filing
FDA accepts for review resubmission of RP1 BLA for advanced melanoma
advanced melanomasource ↗
▲Oral PresentationRP1FiledPresentation
3-year overall survival analysis of RP1 plus nivolumab presented at ASCO 2026
anti-PD-1-failed melanomasource ↗
▲Oral PresentationRP2Presentation
Final data of RP2 monotherapy and in combination with nivolumab presented at ASCO 2026
advanced solid tumorssource ↗
◆Oral PresentationRP2Presentation
Final first-in-human data for RP2 alone and in combination with nivolumab presented at ASCO 2026
advanced solid tumorssource ↗
◆Poster PresentationRP2Presentation
Randomized phase 2/3 trial of RP2 plus nivolumab vs ipilimumab plus nivolumab in ICI-naïve metastatic uveal melanoma
metastatic uveal melanomasource ↗
◆Poster PresentationRP1FiledPresentation
Randomized phase 3 study of RP1 combined with nivolumab vs physician's choice in advanced melanoma progressed on anti-PD-1 and anti-CTLA-4
advanced melanomasource ↗
▲Oral PresentationRP1FiledPresentation
3-year landmark overall survival analysis of RP1 plus nivolumab in anti-PD-1-failed melanoma presented at ASCO 2026
anti-PD-1 failed melanomasource ↗
◆Poster PresentationRP1FiledPresentation
Safety and feasibility of intratumoral injection of RP1 or RP2 in visceral metastases
visceral metastasessource ↗
◆Poster PresentationRP2Presentation
Multicenter open-label study of RP2 combined with atezolizumab plus bevacizumab in HCC or with durvalumab in BTC
advanced hepatocellular carcinoma (HCC) and advanced biliary tract cancer (BTC)source ↗
▲FDA Feedback ReceivedRP1FiledFDA Meeting
FDA alignment on path forward for RP1 BLA resubmission
advanced melanomasource ↗
▼Complete Response LetterRP1FiledFDA Decision
FDA issued Complete Response Letter for RP1 BLA resubmission
▼Restructuring LayoffsCorporate
Substantial scaling back of U.S. manufacturing operations and job eliminations
◆Oral PresentationPresentation
Investor meetings at Jefferies 2026 Biotech on the Beach Summit
◆Oral PresentationPresentation
Fireside chat at Leerink Partners 2026 Global Healthcare Conference
▲Debt Royalty FinancingCorporate
Amendment to Hercules loan agreement with $35M draw and potential $120M additional
◆Oral PresentationPresentation
Replimune management to present at 44th Annual J.P. Morgan Healthcare Conference
▲Enrollment UpdateRP1FiledTrial
IGNYTE-3 enrollment on track, >60 patients enrolled
advanced cutaneous melanomasource ↗
◆Late-BreakerRP1FiledPresentation
Late-breaking abstract on RP1 plus nivolumab presented at SITC 2025
cutaneous melanomasource ↗
◆Poster PresentationRP1FiledPresentation
Poster on RP1 plus nivolumab in anti-PD1-failed cutaneous melanoma at SITC 2025
cutaneous melanomasource ↗
▲FDA Filing AcceptedRP1FiledRegulatory Filing
FDA accepts BLA resubmission for RP1 plus nivolumab in advanced melanoma
advanced melanomasource ↗
▲BLA SubmissionRP1FiledRegulatory Filing
BLA resubmission of RP1 for advanced melanoma accepted by FDA
advanced melanomasource ↗
▲Poster PresentationRP1FiledPresentation
Ad hoc analysis of RP1 plus nivolumab in acral melanoma presented at ESMO 2025
acral melanomasource ↗
◆Trial InitiationRP1FiledTrial
IGNYTE-3 phase 3 trial currently recruiting
melanoma (post anti-PD1 and anti-CTLA-4)source ↗
▲FDA Filing AcceptedRP1FiledRegulatory Filing
BLA resubmission for RP1 accepted by FDA
anti-PD-1 failed melanomasource ↗
Past FDA Catalysts and PDUFA Decisions
How REPL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-06 | RP1 (vusolimogene oderparepvec) in combination with nivolumab | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$433M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 40%
Micro Cap(rank 264 of 658)
Percentile Rank
Replimune Group, Inc. carries a moderate pipeline score (40/100), with $1.6B risk-adjusted pipeline value, led by Vusolimogene oderparepvec in Non-Small Cell Lung Cancer (NSCLC) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vusolimogene oderparepvec Gene therapyMarketedNCT06264180 | Advanced Melanoma | Phase 3 | RECRUITING | 400 | Mar 31, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every REPL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RP2 | advanced solid tumors | Phase 1 | 2026-05-31 | monotherapy or: 19.0%; combination or: 19.1%; disease control rate: 48.9%; median duration response monotherapy: not reached; median duration response combination: 22.1 monthsRead More | Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hill Emily LuisaOfficer (Chief Financial Officer) | Sell | -9,256 215,852 held | $14.28 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in REPL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.6 % (20 %) | 122.27 M | 11.05 M |
REPL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-09 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How REPL ranks across every disease it competes in
Competitive Position is a premium feature
See how REPL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialREPL News
REPLReplimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Replimune Group, Inc. has announced the commercial availability of TUDRIQEV in the U.S. for patients with unresectable advanced cutaneous melanoma who have progressed after PD-1 therapy. This therapy, administered in combination with nivolumab, received accelerated FDA approval based on clinical trial data. A confirmatory Phase 3 trial is ongoing to verify its clinical benefits.
Read more →REPLReplimune to Present at the Cantor Global Healthcare Conference 2026
Replimune Group, Inc. will present at the Cantor Global Healthcare Conference on September 10, 2026. The management team will engage in a fireside chat, which will also be available via webcast. Replimune focuses on developing oncolytic immunotherapies, with its product TUDRIQEV already approved for advanced melanoma treatment.
Read more →REPL▼ -5.1%on this news
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group, Inc. announced the grant of inducement equity awards to Chief Commercial Officer Michelle DiNapoli. The awards include a non-qualified stock option for 150,000 shares and restricted stock units for 100,000 shares, with specific vesting terms. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and are consistent with the company's equity incentive plan.
Read more →REPLReplimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Replimune Group, Inc. reported strong financial results for Q1 2027, highlighted by the FDA's accelerated approval of TUDRIQEV for advanced melanoma. The company is preparing for a commercial launch within 60 days and has secured $150 million in financing to support this effort. Additionally, Michelle DiNapoli has been appointed as Chief Commercial Officer to enhance the company's commercial strategy.
Read more →REPL▲ +13.3%on this news· ran to +26% by day 3
Replimune Announces Pricing of $150 Million Underwritten Offering
Replimune Group, Inc. has announced the pricing of an underwritten offering of 9,701,490 shares of its common stock, raising $150 million. This move is expected to enhance the company's financial resources, enabling further development of its innovative oncolytic immunotherapies. The offering reflects investor confidence in Replimune's growth potential.
Read more →REPL▼ -6.2%on this news· ran to +19% by day 3shared move
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Replimune Group, Inc. announced the FDA's accelerated approval of TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on anti-PD-1 therapy. The approval is based on a 24.2% objective response rate observed in the IGNYTE trial. The treatment was well tolerated, although continued approval may depend on further clinical trials to verify its benefits.
Read more →REPL▲ +107%on this news· ran to +120% by day 1
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Replimune Group, Inc. announced a favorable outcome from the FDA's advisory committee meeting regarding the BLA resubmission for RP1 in advanced melanoma. The committee voted 10 to 3 on the clinical meaningfulness of the efficacy results from the IGNYTE study. The FDA's target action date for the BLA is August 2, 2026.
Read more →REPLReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Replimune Group reported its fiscal fourth quarter and year-end results, highlighting the FDA's acceptance of the BLA resubmission for RP1 in advanced melanoma. The company is actively enrolling patients in its clinical trials for RP1 and RP2, with promising survival data presented at ASCO 2026. However, the company reported a significant net loss and a decrease in cash reserves compared to the previous year.
Read more →REPLReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Replimune Group, Inc. announced that the FDA has accepted its resubmission of the Biologics License Application for RP1 in combination with nivolumab for advanced melanoma. The FDA's action is classified as a complete, class 1 response, with an advisory committee meeting expected in late July. The resubmission aims for accelerated approval based on the IGNYTE clinical trial data.
Read more →REPLReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune Group presented final first-in-human data for RP2 at the 2026 ASCO meeting. The Phase 1 trial involved 85 patients with advanced solid tumors, showing an objective response rate of 19.0% for RP2 monotherapy and 19.1% when combined with nivolumab. The results indicate durable responses and a favorable safety profile, supporting further evaluation in a Phase 2/3 trial.
Read more →REPLReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune Group, Inc. presented promising 3-year overall survival data from the IGNYTE clinical trial at the 2026 ASCO annual meeting. The trial evaluated RP1 plus nivolumab in patients with anti-PD-1 failed melanoma, showing a median overall survival of 32.9 months. Notably, 47.8% of all treated patients survived at three years, with 83.5% survival among responders, highlighting the treatment's durability and effectiveness.
Read more →REPL▲ +85.7%on this news· ran to +113% by day 3shared move
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
Replimune Group, Inc. has announced plans to resubmit its Biologics License Application (BLA) for RP1 following productive discussions with the FDA. The agency has committed to treating the resubmission as urgent, recognizing the unmet needs in advanced melanoma treatment. The BLA is supported by clinical trial data, highlighting the need for new therapies as current options often fail.
Read more →REPL▲ +10.7%on this news
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune Group, Inc. announced its participation in the 2026 ASCO Annual Meeting, where it will present multiple abstracts. Key presentations include a landmark survival analysis from the IGNYTE trial and final results from a Phase 1 study of RP2. The event will showcase advancements in oncolytic immunotherapies for melanoma and other solid tumors.
Read more →REPL▼ -19.5%on this news· ran to -71% by day 1shared move
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune Group received a complete response letter from the FDA for its RP1 biologics license application for advanced melanoma. The company disagrees with the FDA's assessment of the data supporting RP1's efficacy and safety. This decision has led to job cuts and a scaling back of operations, as the company struggles with the regulatory process. The situation highlights concerns over FDA communication and innovation in cancer treatment.
Read more →REPL▼ -6.4%on this news
Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. announced that its management team will present at two upcoming investor conferences: the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit. The presentations will include a fireside chat and 1x1 meetings. Live webcasts will be available on their website.
Read more →REPL▲ +5.8%on this news
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Replimune Group, Inc. reported its fiscal third quarter 2026 financial results, highlighting the acceptance of its BLA resubmission for RP1 by the FDA. The company is preparing for a potential launch, pending FDA approval, with commercial readiness activities in progress. Additionally, Replimune amended its loan agreement to extend its cash runway into early 2027.
Read more →REPLReplimune Group Inc. JPM 2026 Presentation Click to edit Master title style 1 Click to edit Master text styles Igniting a systemic immune response to cancer with oncolytic immunotherapy
Replimune Group Inc. presented at the 2026 JPM Healthcare Conference, highlighting the progress of their RPx oncolytic immunotherapy. The company is set to pursue a PDUFA date of April 10, 2026, for melanoma treatment, leveraging a launch-ready commercial team. The presentation detailed clinical trial advancements and the platform's ability to deliver significant immune responses, particularly in resilient cancer cases. However, the company acknowledged various risks that could affect projected outcomes as they navigate the complexities of development and regulatory approval.
Read more →REPLReplimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc., a clinical stage biotechnology company based in Woburn, MA, has announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026. The company focuses on developing novel oncolytic immunotherapies using its proprietary RPx platform. This platform aims to enhance immunogenic cell death and systemic anti-tumor immune responses, offering potential synergy with existing cancer treatments. A webinar of the presentation will be available on their website for interested investors and stakeholders.
Read more →REPLReplimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Replimune Group, Inc. presented late-breaking abstract data from the IGNYTE trial at the SITC 2025, highlighting the potential of RP1 combined with nivolumab in treating melanoma. The data suggest that this combination may help overcome resistance to immune checkpoint blockade. Additionally, two posters on RP1 were also showcased at the conference.
Read more →About Replimune Group, Inc.
Headquarters500 UNICORN PARK, WOBURN, MA, 01801
BIOPHARMAWATCH ELITE PLUS
Trade the next REPL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime